Tetra Bio-Pharma (TBPMF) Stock Price, News & Analysis

Company Overview

Tetra Bio-Pharma Ltd. is a biopharmaceutical company dedicated to the development and commercialization of novel cannabinoid-based therapies. Headquartered in Ontario, Canada, the company leverages a proprietary drug delivery platform and an experienced research team to create prescription-grade products targeting specific therapeutic indications. Tetra Bio-Pharma operates through two complementary divisions: PharmaDrug Research & Development, which focuses on synthetic and botanical drug candidates, and Symbiosis, a commercial arm that markets topical and over-the-counter health products derived from its cannabinoid library.

The company’s pipeline includes several lead drug candidates designed to address conditions such as neuropathic pain, oncology-related side effects, and inflammatory disorders. Key assets include TB-010, a proprietary formulation intended to relieve chronic pain associated with chemotherapy, and the cannabinoid derivative TB-011, which is being explored for its anti-emetic and analgesic properties. Preclinical and early-stage clinical data support the safety profile of these candidates, and Tetra Bio-Pharma continues to advance them through phased human trials under Health Canada and U.S. Food and Drug Administration guidelines.

Tetra Bio-Pharma serves markets in Canada, the United States, and select international regions through strategic partnerships and distribution agreements. The company’s over-the-counter products, sold under the Symbiosis brand, are available in health and wellness outlets and focus on topical relief of sore muscles and joint pain. Through collaborations with academic institutions and contract research organizations, Tetra Bio-Pharma also maintains a robust R&D network that spans North America and Europe, further strengthening its global presence and scientific capabilities.

Founded in 2012, Tetra Bio-Pharma has evolved from a cannabis cultivation licensee into a fully integrated pharmaceutical developer. The leadership team is headed by Chief Executive Officer Rob Csomos, who brings two decades of experience in life sciences and biotechnology. Supported by a board of directors with backgrounds in clinical research, pharmaceutical manufacturing, and regulatory affairs, the company emphasizes rigorous quality control and adherence to good manufacturing practices (GMP). As Tetra Bio-Pharma advances its clinical programs, it remains committed to addressing unmet medical needs through innovative cannabinoid-based solutions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 185,753 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBPMF Stock Analysis - Frequently Asked Questions

How do I buy shares of Tetra Bio-Pharma?

Shares of TBPMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TBPMF
• CIK: N/A
• Web: www.tetrabiopharma.com
• Phone: (833) 977-7575
• Fax: N/A
• Employees: 33
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A